Francesco Caponigro

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

Ezra E.W. Cohen, Denis Soulières, Christophe Le Tourneau et al. · The Lancet · 2018 · 1.7K citations · Full text

Medicine, Oncology, Pharmacology +11

Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial

Jean-Pascal H. Machiels, Robert I. Haddad, Jérôme Fayette et al. · The Lancet Oncology · 2015 · 392 citations

Medicine, Oncology, Chemotherapy +12

Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin

M. Borner, Patrick Schöffski, Ronald de Wit et al. · European Journal of Cancer · 2002 · 319 citations

Pharmacy, Pharmacokinetics, Pharmacology +11

Phase I and Pharmacokinetic Study of PKC412, an Inhibitor of Protein Kinase C

David Propper, A. McDonald, A. Man et al. · Journal of Clinical Oncology · 2001 · 233 citations

Pharmacy, Oncology, Pharmacology +15

Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial

Jean‐Pascal Machiels, Yungan Tao, Lisa Licitra et al. · The Lancet Oncology · 2024 · 210 citations · Full text

Medicine, Oncology, Pharmacology +16